Medicine
Prevymis 480 mg tablet
Prevymis 480 mg tablet is a prescription medicine containing Letermovir for oral use, marketed by Merck Sharp & Dohme, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store PREVYMIS tablets at 20°C to 25°C (68°F to 77°F), excursions permitted to…
Key facts
- Active ingredient (INN)
- Letermovir
- Brand
- Prevymis
- Strength
- 480 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 4 dose packs, 14 blister pack
- Marketing authorisation holder
- Merck Sharp & Dohme
- Manufacturer
- Merck Sharp & Dohme
- Origin register
- US FDA, United States
- Storage
- Store PREVYMIS tablets at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Store PREVYMIS injection vials at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Store PREVYMIS tablets in the original package until use to protect from moisture. Store in the original carton to protect from exposure to light.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- J05AX18 Letermovir
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 8 November 2017
- Identifiers
- RxCUI 1988652, 1988657, 1988660 +7DailyMed set ID 1b49df80-be4f-47e0-a0b7-123f3e69395bNDC 0006-3076Application NDA209939
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 4 dose pack in 1 carton / 7 tablet, film coated in 1 dose pack | 0006-3076-02 | Merck Sharp & Dohme | 8 November 2017 |
| 14 blister pack in 1 carton / 1 tablet, film coated in 1 blister pack | 0006-3076-04 | Merck Sharp & Dohme | 8 November 2017 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Letermovir
Clinical summary
Letermovir is a cytomegalovirus DNA terminase complex inhibitor indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult and pediatric patients 6 months of age and older and weighing at least 6 kg. MedsAcross supplies Letermovir for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about LetermovirFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- PREVYMIS prescribing information (Merck Sharp & Dohme) · U.S. National Library of Medicine, DailyMed
- Prevymis: European public assessment report (EPAR) · European Medicines Agency
Need Prevymis 480 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.